The article discusses the poor performance of Pfizer Inc. in 2024 compared to other blue-chip stocks. Despite its past success with the COVID-19 vaccine, Pfizer's stock has been under pressure due to declining revenue opportunities. The company is preparing for patent expirations by launching new products.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing